SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

AVR Anteris Technologies Global Corp.

Healthcare · Medical Devices · website · 174 employees
$11.10
52wk 5.20 – 15.47
Overall
43.6
Value
75.4
Growth
0.0
Health
69.2
Quality
0.0
Momentum
68.7
Dividend
—
Price
About Anteris Technologies Global Corp.

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Price analytics

Returns

1 day 3.1%
1 week 3.8%
1 month -7.0%
3 months -27.5%
6 months 46.1%
1 year 71.8%
3 years -45.8%

Risk

Volatility (1y ann.) 78.8%
Beta vs ASX 200 1.43
Sharpe (1y) 1.01
VaR 95% (1-day) -6.4%
Max drawdown (1y) -42.9%
Off 1-year high -27.5%

Technicals

RSI(14) 43
vs 50DMA -5.9%
vs 200DMA 8.6%
Trend Golden cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 75.4
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
69
Price / Sales
0
Growth 0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
0
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health 69.2
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
100
Debt / Equity
100
Quality (Profitability & Cash Flow) 0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 68.7
6-month return vs ASX 200
100
Price vs 200-day average
79
Price vs 50-day average
21
Position in 52-week range
57

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$1.08B
P/E (trailing)
—
P/E (forward)
-5.12
EPS (trailing)
-2.81
Dividend yield
—
Payout ratio
0.0%
Beta
—
EV / EBITDA
-7.93
Price / Book
3.06
ROE
-74.7%
Operating margin
-3,072.1%
Net margin
0.0%
Total cash
$256.87M
Total debt
$3.32M
Current ratio
14.20
Debt / Equity
0.01
Free cash flow
$-51.13M
Avg volume
14,710
Latest annual results (FY ending 31 Dec 2025)
  • Revenue$1.91M
  • Gross profit$1.34M
  • Operating income-$94.14M
  • Net income-$94.14M
  • Diluted EPS-2.55
  • Free cash flow-$79.76M
  • Net debt-$10.29M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4